A Phase I/II Clinical Study to Investigate the Safety, Tolerability and Efficacy of ICP-022 in Chinese Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Orelabrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors InnoCare Pharma
- 06 Nov 2019 Results presented at the 61st Annual Meeting and Exposition of the American Society of Hematology
- 17 Jun 2019 Status changed from recruiting to active, no longer recruiting.
- 09 Aug 2018 Status changed from not yet recruiting to recruiting.